Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Therapeutic Immunity? Plasma, Immunoglobulin Therapies Shield CSL From Global Financial Crisis

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Australian-headquartered CSL Limited has not been affected by the global financial crisis CEO Brian McNamee told analysts Feb. 18 during a half-year earnings call. Australia's financial year begins July 1 and ends June 30
Advertisement

Related Content

First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine
First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine
U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition
U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition
Shortage Of Blood Products Means Record Sales For China Biologic Products
Shortage Of Blood Products Means Record Sales For China Biologic Products
Advertisement
UsernamePublicRestriction

Register

SC070899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel